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TranscriptomesSand ﬂies are blood-feeding insects and vectors of the Leishmania parasite. For many years, saliva of these
insects has represented a gold mine for the discovery of molecules with anti-hemostatic and immuno-
modulatory activities. Furthermore, proteins in sand ﬂy saliva have been shown to be a potential vaccine
against leishmaniasis and also markers of vector exposure. A bottleneck to progress in these areas of
research has been the identiﬁcation of molecules responsible for the observed activities and properties
of saliva. Over the past decade, rapid advances in transcriptomics and proteomics resulted in the
completion of a number of sialomes (salivary gland transcriptomes) and the expression of several recom-
binant salivary proteins from different species of sand ﬂy vectors. This review will provide readers with a
comprehensive update of recent advances in the characterization of these salivary molecules and their
biological activities and offer insights pertaining to their protective effect against leishmaniasis and their
potential as markers of vector exposure.
Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creative-
commons.org/licenses/by-nc-nd/3.0/).1. Introduction
Phlebotomine sand ﬂies are blood feeders and vectors of Leish-
mania parasites, causative agents of the neglected disease leish-
maniasis. Sand ﬂies are found in tropical and temperate regions
of the world where the majority of medically important vector spe-
cies belong to the genus Phlebotomus in the Old World and to the
genus Lutzomyia in the New World.
During the process of getting a blood meal, sand ﬂies damage
the skin of the host with their proboscis and provoke an immediate
response by the host’s hemostatic system to prevent blood loss.
Sand ﬂies have developed creative ways to circumvent this
problem by producing pharmacologically active components in
their saliva that can counteract the host’s hemostatic system
(Charlab et al., 1999; Ribeiro and Francischetti, 2003). Over two
decades various groups have progressively investigated several
aspects of sand ﬂy saliva, exploring its composition and the biolog-
ical activity of its salivary proteins and their potential use in
biomedicine. In this review we will provide an account of the pro-
gress made in these different disciplines over the past decade.2. Saliva in hemostasis, inﬂammation and immunity
The saliva of sand ﬂies is composed of a limited number of
secreted proteins (Table 1), and in some cases nucleosides and
nucleic acids (Ribeiro et al., 1999; Ribeiro and Modi, 2001).
Approximately 20–40 abundant secreted proteins are visible on a
SDS–PAGE gel (Anderson et al., 2006; Valenzuela et al., 2001a,
2004), no study has yet conﬁrmed the presence of secreted lipids
or other components in the saliva of these insects (Charlab et al.,
1999). Most salivary proteins are soluble and only a few nano-
grams or femtograms of each molecule are injected into the skin
of the host. Despite the low complexity of sand ﬂy saliva, the
molecules it contains are potent and exert a profound effect on
the host physiology at very low concentrations altering various
important biological systems of the host as described below.
2.1. Hemostasis
One of the primary functions attributed to sand ﬂy saliva (and
to saliva of other blood-feeders) is to counteract host hemostasis
by inhibiting the blood coagulation cascade, platelet aggregation
and vasoconstriction (Ribeiro and Francischetti, 2003). Thus far,
saliva of sand ﬂies was shown to have a vasodilator (Ribeiro
et al., 1989, 1999; Ribeiro and Modi, 2001), an apyrase that works
Table 1
Sand ﬂy salivary gland transcriptomes.
Sand ﬂy salivary
gland transcriptomes
Parasites associated
with sand ﬂy species
Disease caused
by parasites
Number of high quality
sequences per transcriptome
Number of full-length secreted
proteins per transcriptome
References of completed
sand ﬂy transcriptomes
Lu. longipalpis L. infantum chagasi VL 550 35 Valenzuela et al. (2004)
Lu. intermedia L. braziliensis CL/MCL 1395 40 De Moura et al. (2013)
Lu. ayacuchensis L. mexicana, L.
peruviana
CL 768 64 Kato et al. (2013)
P. papatasi Tunisia L. major CL 1603 49 Abdeladhim et al. (2012)
P. duboscqi Mali L. major CL 988 38 Kato et al. (2006)
P. duboscqi Kenya L. major CL 924 32 Kato et al. (2006)
P. sergenti L. tropica, L. aethiopica CL 853 25 Rohousova et al. (2012)
P. arabicus L. tropica CL 985 34 Hostomska et al. (2009)
P. argentipes L. donovani VL 603 23 Anderson et al. (2006)
P. ariasi L. infantum VL 538 24 Oliveira et al. (2006)
P. perniciosus L. infantum VL 535 20 Anderson et al. (2006)
P. perniciosus Madrid
Spain
L. infantum VL – 15 Martin-Martin et al. (2013)
P. tobbi L. infantum VL/CL 997 32 Rohousova et al. (2012)
P. orientalis Addis
Zemen
L. donovani VL 835 25 Vlkova et al. (2014)
P. orientalis Melka
Werer
L. donovani VL 749 26 Vlkova et al. (2014)
L., Leishmania; CL, cutaneous leishmaniasis; MCL, muco-cutaneous leishmaniasis; VL, visceral leishmaniasis.
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adenosine diphosphate (APD) (Charlab et al., 1999; Hamasaki
et al., 2009; Valenzuela et al., 2001b), an inhibitor of the blood
coagulation cascade (Charlab et al., 1999) and an inhibitor of the
classical pathway of the complement cascade (Cavalcante et al.,
2003). These biological activities counteract the redundant and
efﬁcient hemostatic system consequently facilitating the acquisi-
tion of a blood meal by sand ﬂies.
2.2. Immunomodulation
Though sand ﬂies do not feed for a long time on their host, they
depend mostly on the salivary anti-hemostatic components to
acquire a blood meal. However, a number of immuno-modulatory
activities have been reported from the saliva of sand ﬂies (Andrade
et al., 2007; Prates et al., 2012; Rohousova and Volf, 2006). The
exact role of these immunomodulatory components in blood feed-
ing still needs to be elucidated and may be linked prospectively to
other anti-hemostatic activities. Nevertheless, their potential use
in biomedicine makes them an attractive target as therapeutic
molecules for inﬂammatory diseases. Furthermore, these
immuno-modulatory activities may facilitate pathogen transmis-
sion and its establishment.
One of the ﬁrst immuno-modulatory activities shown in sand
ﬂy saliva was the inhibitory effect of Lutzomyia longipalpis saliva
on the activation of T cells and macrophages by inhibiting the
expression of Th1 type cytokines and inducing the expression of
Th2 cytokines by activated macrophages (Hall and Titus, 1995;
Soares et al., 1998; Theodos and Titus, 1993). Saliva of this sand
ﬂy was also shown to have a chemotactic activity for macrophages
(Teixeira et al., 2005). Similarly, Phlebotomus papatasi saliva was
shown to have the same effect on T cells down-regulating the pro-
duction of Th1 cytokines and up-regulating the production of Th2
cytokines (Abdeladhim et al., 2011; Mbow et al., 1998; Rogers and
Titus, 2003). Further work needs to be done in identifying the sal-
ivary proteins responsible for the inhibitory effect in T cells and the
mechanism of this inhibition.
Dendritic cells (DC) are potent antigen presenting cells special-
ized in the initiation of the immune response by direct activation
of naïve T lymphocytes and induction of their differentiation to spe-
ciﬁc subtypes. P. papatasi and Phlebotomus duboscqi saliva inhibited
the ability of DC to present antigens (Carregaro et al., 2008). Sand ﬂy
saliva induced the sequential production of prostaglandin E2 (PGE2)and IL-10 by DC. PGE2 and IL-10 then acted on DC in an autocrine
manner reducing the expression of MHC-II and CD86 co-stimula-
tory molecules on their surface (Carregaro et al., 2008).
Neutrophils are one of the ﬁrst lines of defense against infection
(Abi Abdallah and Denkers, 2012). It was recently reported that sal-
iva of sand ﬂies has an effect on the function of neutrophils. Lu.
longipalpis saliva increased the apoptosis of neutrophils directly
in a FasL-mediated caspase-dependent manner (Prates et al.,
2011). On the other hand, as explained above the expression of
PGE2 and IL-10 by DC induce the inhibition of the expression of
neutrophil chemotactic factors MIP-1a, TNF-a and Leukotriene B4
and consequently diminishing neutrophil migration during speciﬁc
antigen-induced inﬂammation (Carregaro et al., 2008).
It was recently shown that Lu. longipalpis saliva induces the for-
mation of lipid bodies and PGE2 in macrophages via the ERK-1/2
and PKC-a signaling pathways (Araujo-Santos et al., 2010). These
lipid bodies are cytoplasmic organelles involved in arachidonic
acid metabolism that form eicosanoids in response to inﬂamma-
tory stimuli (Araujo-Santos et al., 2010). The production of PGE2
by Lu. longipalpis saliva will probably induces anti-inﬂammatory
activities similar to those observed in P. papatasi saliva
(Carregaro et al., 2008).
2.3. Effect of saliva on leishmaniasis
2.3.1. Exacerbating effect of saliva
The above-mentioned effects of sand ﬂy saliva on the host’s
hemostatic and immune systems results in a different environ-
ment at the feeding site and this modiﬁed environment has been
shown to favor the establishment of Leishmania parasites. In mice,
co-injection of Lu. longipalpis or P. papatasi saliva with Leishmania
major resulted in an exacerbated disease reﬂected by a larger ulcer
that developed to a necrotic lesion compared to the injection of L.
major alone (Belkaid et al., 1998; Theodos et al., 1991; Titus and
Ribeiro, 1988). Similar results were observed with Leishmania bra-
ziliensis braziliensis (Samuelson et al., 1991) or Leishmania mexicana
amazonensis (Theodos et al., 1991) parasites and saliva of
Lutzomyia intermedia and Lu. longipalpis, respectively.
2.3.2. Effect of adaptive immunity to saliva
There is a signiﬁcant body of literature demonstrating that
exposure to saliva induces an immune response in animals that
mostly confers protection against leishmaniasis. The ﬁrst line of
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saliva (Belkaid et al., 1998) or previously exposed to bites of unin-
fected P. papatasi (Kamhawi et al., 2000) were protected against L.
major infection initiated by needle challenge or infected sand ﬂies,
respectively. Protection from leishmaniasis conferred by previous
exposure to sand ﬂy saliva or to bites was later reported for other
sand ﬂy and parasite species (Teixeira et al., 2014). The protective
effect of sand ﬂy saliva has been attributed to either the neutraliza-
tion of the exacerbative effect of saliva (Belkaid et al., 1998; Morris
et al., 2001) or to the induction of a Th1 cellular immune response
in a form of a delayed-type hypersensitivity response (DTH) that is
detrimental for the establishment of the Leishmania parasite
(Kamhawi et al., 2000).
Although the majority of studies reproduced the protective
effect of previous exposure to saliva, for the New World sand ﬂy
Lu. intermedia it resulted in exacerbation of the disease (de
Moura et al., 2010, 2013; Weinkopff et al., 2014). Mice pre-exposed
to Lu. intermedia salivary gland extract (SGE) and challenged with
L. braziliensis plus SGE showed a signiﬁcant decrease in CXCL10
expression paralleled by an increase in IL-10 expression (de
Moura et al., 2010).3. From saliva and activities to transcriptomes and
characterization of the bioactive molecules
Pharmacological and immuno-modulatory activities were
described in the saliva of sand ﬂies but only one protein with
attributable activities was identiﬁed; the salivary vasodilator and
immunomodulator protein maxadilan (Lerner et al., 1991). This
remained the only characterized molecule from the saliva of a sand
ﬂy despite the diverse activities reported from several vector spe-
cies. Three salivary proteins with biological activity, an apyrase, a
hyaluronidase and a 50 nucleotidase, and 5 other proteins of
unknown function were later on identiﬁed from Lu. longipalpis by
PCR subtraction technology (Charlab et al., 1999). Considering that
about 30 phlebotomine species transmit leishmaniasis (Desjeux,
2004) having only partial information on the salivary transcripts
present of P. papatasi and Lu. longipalpis (Charlab et al., 1999;
Valenzuela et al., 2001a) reﬂected the paucity of our knowledge
of sand ﬂy saliva up to that point. At the turn of the century a
new technology hit the vector biology ﬁeld, the transcriptomics
revolution, where salivary glands transcriptomes from different
blood-feeding arthropods including the salivary gland transcrip-
tome of Lu. longipalpis were completed (Ribeiro and Francischetti,
2003; Valenzuela et al., 2004). This was followed, by the comple-
tion of salivary gland transcriptomes from relevant sand ﬂy vectors
including the salivary transcriptomes from Phlebotomus ariasi
(Oliveira et al., 2006), Phlebotomus perniciosus, Phlebotomus argent-
ipes (Anderson et al., 2006), P. duboscqi (Kato et al., 2006), Phlebo-
tomus arabicus (Hostomska et al., 2009), Phlebotomus tobbi,
sergenti sergenti (Rohousova et al., 2012), P. papatasi (Abdeladhim
et al., 2012), Lutzomyia ayacuchensis (Kato et al., 2013), Lu. interme-
dia (de Moura et al., 2013) and Phlebotomus orientalis (Vlkova et al.,
2014). It is important to note that the majority of currently avail-
able transcriptomes are from sand ﬂies of the genus Phlebotomus
and more salivary transcriptomes of sand ﬂies from the Americas
are need (Fig. 1). Transcriptomic analysis of different species from
the Old World and the few species from New World are providing
insights into the nature of the array of molecules present in sand
ﬂy saliva. Fifteen salivary gland cDNA libraries representing twelve
different sand ﬂy species resulted in the identiﬁcation of distinct
families of secreted proteins (Table 2). Some of the salivary pro-
teins in some sand ﬂy species have multiple members, probably
due to gene duplication events, forming a large family of proteins
(Table 3). Examples include the small odorant binding family ofsalivary proteins (SP15 like) in P. duboscqi (Kato et al., 2006) and
P. papatasi (Abdeladhim et al., 2012) and the C-type lectin-like pro-
teins in Lu. longipalpis (Valenzuela et al., 2004). Most of the listed
protein families in Tables 2 and 3 are found in all sand ﬂy species
studied so far; others are speciﬁc only to New World species and
only few appear to be speciﬁc for Old World sand ﬂies. The infor-
mation gathered by these salivary gland transcriptomes represents
a signiﬁcant advancement compared to the few molecules known
prior to the era of transcriptomics.4. From transcriptomics to functional genomics: assigning
activities to molecules
The vector biology ﬁeld as well as many other ﬁelds faced a new
challenge: the post-genomics era. For sand ﬂies, it is better stated
as the post-transcriptomics era since there is no genome of sand
ﬂies available yet. Despite the identiﬁcation of many salivary tran-
scripts we still faced the challenge of how to connect this informa-
tion to biological activities previously described from saliva of
these insects (Table 2) and how to utilize this gigantic source of
new information. Bioinformatic approaches helped this transition
by providing the means to organize and annotate newly described
transcripts towards the identiﬁcation of proteins with predicted
function; for ‘‘unknown’’ proteins the challenge remains.
4.1. Deciphering the function of unknown salivary proteins
There are a number of salivary proteins in the transcriptomes of
sand ﬂies with no homologies to other proteins in accessible data
banks; therefore, their function is difﬁcult to predict. Various strat-
egies such as expression of recombinant proteins in bacteria or
mammalian cells, DNA vaccination and reverse antigen screening
were developed to identify the function of these proteins. These
approaches have resulted in the discovery of new functions, and
new properties of salivary molecules including their potential as
markers of exposure and as vaccines against leishmaniasis.
4.1.1. Salivary proteins with anti-hemostatic properties
4.1.1.1. The yellow family of salivary proteins, biogenic amine binding
proteins. For many years the function of yellow proteins in sand
ﬂies, namely LJM11, LJM17 and LJM111, was unknown. This is
one of the most abundant families of salivary proteins and it is
found in all sand ﬂy transcriptomes. Recently, it was demonstrated
that all three members of the yellow family of proteins from saliva
of the sand ﬂy Lu. longipalpis bind biogenic amines, including sero-
tonin, catecholamines, and histamine (Xu et al., 2011). Biogenic
amines are a group of pro-hemostatic and pro-inﬂammatory medi-
ators that potentially obstruct feeding. The crystal structure of
LJM11 was solved and represented the ﬁrst structure described
for any sand ﬂy salivary protein up to date (Xu et al., 2011).
LJM11 has a six bladed-propeller fold and each blade consists of
a four-stranded sheet. This structure forms a central channel that
binds biogenic amines (Xu et al., 2011). LJM11 and LJM111 share
a similar structure the only difference being the surface charge dis-
tribution; LJM11 has a positive surface charge while LJM111 has a
more neutral surface charge (Xu et al., 2011). The amino acids
responsible for the binding to biogenic amines were identiﬁed
(Xu et al., 2011) and are conserved in yellow related proteins from
other sand ﬂy species as recently reported for P. papatasi
(Abdeladhim et al., 2012). This suggests that sand ﬂy yellow
proteins may also share this biological activity.
4.1.1.2. Lufaxin-like molecules and Lufaxin (LJL143), anticoagulants of
sand ﬂy saliva. The anticoagulant from sand ﬂies has remained
elusive for many years. The activity was identiﬁed but the
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C-type lectin-like protein from Lu. longipalpis co-eluted with the
anticoagulant activity leading to it’s identiﬁcation as the anticoag-
ulant. However, this initial characterization could not be conﬁrmed
due to the lack of the activity of the recombinant protein. Further-
more, the same anticoagulant activity was also present in P. papat-
asi and P. duboscqi saliva that do not contain the C-type lectin
family of proteins arguing against it being the molecule responsi-
ble for the salivary anticoagulant activity. Only recently expression
and testing of a number of recombinant salivary proteins from the
Lu. longipalpis salivary gland transcriptome identify LJL143 as the
protein responsible for the anticoagulant activity. This 32 kDa
protein was consequently renamed Lufaxin (Lutzomyia Factor Xa
inhibitor) (Collin et al., 2012). Importantly, homologues of the tran-
script coding for this protein are present in all sand ﬂies studied so
far suggesting that these Lufaxin-like proteins are the anticoagu-
lants of all New world and Old world sand ﬂies (Abdeladhim
et al., 2012; Anderson et al., 2006; de Moura et al., 2013;
Hostomska et al., 2009; Kato et al., 2006, 2013; Martin-Martin
et al., 2013; Oliveira et al., 2006; Valenzuela et al., 2004; Vlkova
et al., 2014).
Lufaxin is a novel protein with no similarities to any other pro-
tein in accessible databases and it was shown to be a potent and
speciﬁc inhibitor of the coagulation Factor Xa (FXa). This coagula-
tion factor (FXa) is one of the most important proteases in the
blood coagulation cascade where both extrinsic and intrinsic
pathways converge leading to prothrombinase assembly with sub-
sequent thrombin generation and ﬁbrin formation. Importantly,
Lufaxin was also shown to be of great consequence in inﬂamma-
tion. FXa activates receptor PAR1 or PAR2 in different cell types
enabling and promoting inﬂammation and immune modulation.
Lufaxin was shown to act on PAR receptors inhibiting the activity
of FXa and to attenuate inﬂammation and prevent arterial
thrombosis in a mouse model (Collin et al., 2012).4.1.1.3. The SP15-like odorant binding family of proteins, contact
activation inhibitors:. Transcriptomic analysis from other sand ﬂy
species revealed that this family of proteins is common and abun-
dant (Table 2). Phylogenetic studies show that these proteins haveP. perniciosu
(Spain, Italy) 
Lu. longipalpis 
(Brazil) 
Lu. ayachunensis 
(Ecuador) 
P. ariasi 
(France) 
Lu. intermedia 
(Brazil) 
Lu. olmeca 
(Mexico)* 
P. papatasi 
(Tunisia) 
P. duboscqi 
(Mali) 
Fig. 1. Presentation of the sand ﬂies saliva published transcriptomes from different r
File:World_map_blank_without_borders.svg). ⁄In progress.some resemblance to small odorant binding proteins in insects
(Abdeladhim et al., 2012), however, the biological activity of this
family of proteins remained elusive for many years. Recently,
PdSP15 from saliva of the sand ﬂy P. duboscqi, a member of this
family of proteins, was shown to inhibit the activation of FXII
and FXI, as well as the cleavage of FXI by FXIIa or thrombin, and
to inhibit other anionic surface-mediated reactions (Alvarenga
et al., 2013). The relevance of these ﬁndings is that anionic surfaces
help to stabilize complexes of the blood coagulation cascade such
as FXIIa with FXI and also complexes involved in inﬂammatory
processes such as high molecular weight kininogen, prekallikrein,
thrombin and FXI.
This family of proteins may prevent downstream effects of mast
cell activation caused by the bite of the sand ﬂy including the for-
mation of bradykinin, an inducer of pain. The targeting of anionic
surfaces rather than speciﬁc proteins by this family of proteins
suggests they may inhibit other processes of hemostasis and
inﬂammation and may have some therapeutic uses that need
further exploration.4.1.1.4. LJL138 or Lundep, an endonuclease. LJL138 is a salivary
protein present in the transcriptome of Lu. longipalpis and encodes
an endonuclease, however, for a long time the predicted activity of
this protein was never tested or conﬁrmed (Valenzuela et al.,
2004). Renamed Lundep, the activity of this protein was recently
established as a potent endonuclease (Table 2) (Chagas et al.,
2014). This protein contains the NUC-motif indicative of nonspe-
ciﬁc double and single stranded DNA and RNA endonuclease
activity.
The DNase activity of Lundep may contribute to the anti-throm-
botic and anti-inﬂammatory functions of Lu. longipalpis saliva by
hydrolyzing the DNA scaffold of neutrophil extracellular traps
(NETs) at the biting site. Lundep may assist blood-meal intake by
lowering the local viscosity induced by the release of host DNA
at the injury site caused by the bite of the insect when taking a
blood meal. In fact, anti-Lundep antibodies signiﬁcantly decreased
the feeding success of female Lu. longipalpis ﬂies in passively
immunized mice (Chagas et al., 2014).s  
P. arabicus 
(Israel) 
P. argentipes 
(India) 
P. orientalis 
(Ethiopia, addis Zemen) 
P. orientalis 
(Ethiopia, Melka Werer) 
P. papatasi 
(Israel) 
P. tobbi
(Turkey) 
P. sergenti 
(Israel)
P. duboscqi 
(Kenya)
egion of the world (Background map from: http://commons.wikimedia.org/wiki/
Table 2
Sand ﬂy salivary proteins with known biological activity.
Sand ﬂy salivary
transcriptomes
Biological activities of salivary proteins (molecular weight) Anti-
inﬂammatory
/anti-arthritis
Inhibitor of contact
activation, heparin
binding
Biogenic
amine
binding
proteins
Anti-
coagulant,
inhibitor
of factor
Xa
Ecto ADPase,
inhibitor of
platelet
aggregation
DNAse
activity
Degradation of
hyaluronan hydrolyzis
of chondroitin sulfates
Purine metabolism
hydrolysis of
adenosine
Vasodilator
and inhibitor
of platelet
aggregation
Nucleotidase Vasodilator
Small odorant binding
protein (OBP) – lile
(15 kDa)
Yellow
protein
(45 kDa)
Lufaxin/
Lufaxin
like
(32 kDa)
Apyrase
(‘36 kDa)
Endonuclease
(44 kDa)
Hyaluronidase
(42 kDa)
Adenosine
deaminase
(56 kDa)
Adenosine 50
Nucleotidase
(61 kDa)
Maxadilan
peptide
(6 kDa)
LJM111
Lu. longipalpis
(Valenzuela
et al., 2004)
LJM04 LJM11a,
LJM17a,
LJM111a (Xu
et al., 2011)
LJL143
(Lufaxin)a
(Collin
et al.,
2012)
LuloAPYa
(Charlab
et al., 1999)
LJL138
(Lundep)a
(Chagas et al.,
2014)
LuloHYAa (Cerna et al.,
2002; Charlab et al.,
1999; Rohousova
et al., 2012)b
ADAa (Charlab
et al., 1999)
Lulo5NUCa
(Charlab
et al., 1999)
Maxadilana
(Lerner and
Shoemaker,
1992)
LJM111a
(Grespan
et al., 2012)
Lu. intermedia
(De Moura
et al., 2013)
Linb-7, 8, 28, 59 Linb-21 Linb-17 Linb-35 Linb-46 Linb-54 Linb-147
Lu. ayacuchensis
(Kato et al.,
2013)
LayS32–37, 48–72 LayS22–24,
117, 118
LayS120–
132
LayS8–14,
16–21
LayS147
P. papatasi
Tunisia
(Abdeladhim
et al., 2012)
PPTSP12–15 PPTSP42, 44 PPTSP34b
(Collin
et al.,
2012)
PPTSP36 b
(Ribeiro
et al., 1989b)
bCerna et al. (2002)) bRibeiro et al.
(1999), Charlab
et al. (1999),
Carregaro et al.
(2011)
Adenosine
and 50-AMPb
(Ribeiro et al.,
1999)
P. duboscqi Mali
(Kato et al.,
2006)
PduM02–03, 06–07, 12,
31–32, 49–50, 57–58, 60,
62, 99a (Alvarenga et al.,
2013)
PduM10, 35 PduM04–
05b (Collin
et al.,
2012)
PduM38–39 a
(Hamasaki
et al., 2009)
bCerna et al. (2002) PduM73
P. duboscqi
Kenya (Kato
et al., 2006)
PduK01–03, 40–42, 49,
56–58, 109–110a
(Alvarenga et al., 2013)
PduK04–06,
86
PduK70b
(Collin
et al.,
2012)
PduK50 a
(Hamasaki
et al., 2009)
bCerna et al. (2002) PduK60
P. sergenti
(Rohousova
et al., 2012)
PsSP9–11, 14–15, 54–55 PsSP18–20,
22, 26
PsSP49 PsSP40–42 bCerna et al. (2002),
Rohousova et al.
(2012)
P. arabicus
(Hostomska
et al., 2009)
PabSP2, 45, 63–64, 93, PabSP26, 53 PabSP34,
32
PabSP39, 40–
41
PabSP49 PabSP72b (Rohousova
et al., 2012)
P. argentipes
(Anderson
et al., 2006)
PagSP01, 02, 07, 12, 13 PagSP04 PagSP09 PagSP03 b
(Ribeiro
et al., 1989b)
PagSP11 bRohousova et al.
(2012)
Adenosine
and 50-AMPb
(Ribeiro et al.,
1999)
P. ariasi (Oliveira
et al., 2006)
ParSP03, 06, 08 ParSP04,
04B
ParSP09 ParSP01 ParSP10
P. perniciosus
(Anderson
et al., 2006)
PpeSP02, 09, 11 PpeSP03,
03B
PpeSP06 PpeSP01, 01B
b (Ribeiro
et al., 1989b)
PpeSP32 bRohousova et al.
(2012)
P. perniciosus
Madrid Spain
(Martin-
Martin et al.,
2013)
SP02, 09, 11 SP03B SP06 SP01,01B b
(Ribeiro
et al., 1989b)
bRohousova et al.
(2012)
(continued on next page)
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activity
4.1.2.1. LJM111, a potent anti-inﬂammatory molecule. In addition to
binding biogenic amines (Xu et al., 2011), LJM111, was shown to
have another function (Table 2). LJM111 (but not LJM11 or
LJM17) was characterized as a potent anti-inﬂammatory molecule.
Recombinant LJM111 was shown to inhibit IL-17, TNF-a and IFN-c
production by leukocytes obtained from lymph node suspension
following in vitro stimulation with methylated bovine serum albu-
min (mBSA). LJM111 also inhibited neutrophil migration in a dose
dependent manner following mBSA-challenge of Ovalbumin
(OVA)-immunized mice used as a model of OVA-induced neutro-
phil migration (Grespan et al., 2012). Furthermore, LJM111
reduced the hypernociception (pain) in a model of arthritis and
inhibited the production of pro-inﬂammatory molecules conse-
quently reducing in vivo neutrophil recruitment.
DCs that emigrate to inﬂamed joints produce pro-inﬂammatory
mediators that support expansion and differentiation of Th1 and/or
Th17 cells, which play a pathologic role in arthritis (Carregaro
et al., 2011). LJM111 affected the maturation of DCs leading to
increased IL-10 production and reduced synthesis of TNF-a
(Grespan et al., 2012).
4.1.2.2. Nucleosides. Sand ﬂy saliva triggers an inﬂammatory
response characterized by a cellular inﬂux and suppression of
hemostatic and immune mechanisms. The saliva of P. papatasi
contains large amounts of adenosine and 50-AMP. These two non-
proteic components were shown to block antigen presentation by
DCs by inhibiting TNF-a and IL-12p40, increasing IL-10 production
and interfering with Th17 cell activation consequently suppressing
the inﬂammatory immune response (Carregaro et al., 2011).
4.1.3. Direct effects of isolated sand ﬂy salivary components on disease
4.1.3.1. Effects of hyaluronidase on leishmaniasis. Hyaluronidase
activity was originally described in saliva of the sand ﬂy Lu.
longipalpis (Charlab et al., 1999) and was later shown to be present
in the saliva of Old World sand ﬂies (Table 2) (Cerna et al., 2002;
Rohousova et al., 2012; Vlkova et al., 2014; Volfova et al., 2008).
The salivary hyaluronidase plays an important role in blood meal
acquisition, by degrading hyaluronan (HA), abundant in host skin,
and probably increasing tissue permeability for other salivary com-
ponents (Volfova et al., 2008). Using commercially available hyal-
uronidase, Volfova et al. (2008) demonstrated that the activity of
this enzyme facilitated transmission and establishment of L. major
parasites. Importantly, fragments of HA were shown to have
immunomodulatory properties; they affect maturation and migra-
tion of dendritic cells, induction of iNOS, chemokine secretion by
macrophages and proliferation of activated T cells (Volfova et al.,
2008).
4.1.3.2. Impact of Lundep on leishmaniasis. As an endonuclease, the
activity of Lundep had a direct impact on the development of Leish-
mania parasites. Leishmania parasites evade killing by neutrophils
either by blocking the oxidative burst and entering a non-lytic
compartment unable to fuse with lysosomes or by resisting the
leishmanicidal activity of parasite-induced NETs (Gabriel et al.,
2010). Chagas et al. (2014) demonstrated that Lundep can
effectively facilitate the survival of L. major parasites. Survival of
Leishmania in neutrophils has been reported as a mechanism for
silent uptake by macrophages favoring establishment of
Leishmania infections (Peters et al., 2008).
4.1.4. Sand ﬂy salivary proteins in auto-immunity
Pemphigus foliaceus (PF) is an auto-immune disease targeting
the skin. It is mediated by pathogenic IgG4 anti-epidermal autoan-
tibodies against desmoglein 1 (Dsg1) causing epidermal cell
Table 3
Sand ﬂy salivary proteins with unknown function.
Sand ﬂy salivary
transcriptomes
(References)
Families of salivary proteins
Antigen 5
(30 kDa)
Large OBP/
D7
(28 kDa)
Silk related/
collagen
binding
(32 kDa)
C-type
lectin
(15 kDa)
RGD-containing
family of
proteins
(5 kDa)
10 kDa
family
(10 kDa)
16 kDa
protein
(16 kDa)
Glutathione S
transferase like
proteins
(27 kDa)
11.5 kDa
protein
(11 kDa)
ML domain
peptide
family
(14 kDa)
Small toxin-
like proteins
(7 kDa)
37 kDa
protein
(37 kDa)
9 kDa
protein
(9 kDa)
Lu. longipalpis
(Valenzuela et al.,
2004)
LJL34 LJL13 LJL04 LJL91, 15,
18 LJM10,
06 LJS142
LJL35 LJM19
LJS192,
169
LJL17 LJM78 LJS201
Lu. intermedia (De
Moura et al., 2013
Linb-13 Linb-26, 42 Linb-14,
15, 22, 48
Linb-1, 2,11,36 Linb-19,
38, 44
Linb-29,
37,55, 58, 33
Linb-40, 41,
43, 60,
52,53,88,
Lu. ayacuchensis
(Kato et al., 2013)
LayS73–
81
LayS95–
103
LayS83–93 LayS120–
LayS132
LayS44–47 LayS128,
129, 130–
132
M8D12
(BAM69094)
LayS6, 7,
142
P. papatasi Tunisia
(Abdeladhim
et al., 2012)
PPTSP29 PPTSP28a-
28c, 30
PPTSP32 PPTSP14.3 PPTSP56
P. duboscqi Mali
(Kato et al., 2006)
PduM48 PduM01,
29, 46–47,
77
PduM33–34,
72, 87
PduK84
P. duboscqi Kenya
(Kato et al., 2006)
PduK68,
107
PduK34–
35, 69, 78,
103
PduK45–46,
83
P. sergenti
(Rohousova et al.,
2012)
PsSP52 PsSP4–5, 7 PsSP44
P. arabicus
(Hostomska et al.,
2009)
PabSP5 PabSP20,
54, 59
PabSP29–31 PabSP63,
64
PabSP11–15
P. argentipes
(Anderson et al.,
2006)
PagSP05 PagSP10,
25
PagSP06 PagSP73
P. ariasi (Oliveira
et al., 2006)
ParSP05 ParSP07,
12, 16, 84
ParSP02 ParSP25 ParSP17
P. perniciosus
(Anderson et al.,
2006)
PpeSP07 PpeSP04,
04B, 10
PpeSP05 PpeSP19
P. perniciosus Madrid
Spain (Martin-
Martin et al.,
2013)
SP04, 04B
P. tobbi (Rohousova
et al., 2012)
PtSP77–79 PtSP42, 44,
54, 56–58,
60
PtSP27–29 PtSP73,75, 76
P. orientalis Addis
Zemen (Vlkova
et al., 2014)
PorASP74,
76,
PorASP46,
48, 122
PorASP86 PorASP150 PorASP106
P. orientalis Melka
Werer (Vlkova
et al., 2014)
PorMSP6,
8
PorMSP28,
38, 43, 67
PorMSP15 PorMSP162 PorMSP65
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is a calcium-binding transmembrane glycoprotein component of
epithelial cells (Wheeler et al., 1991).
In Brazil, endemic areas of PF, known as Fogo Selvagen, overlap
with leishmaniasis endemic areas (Diaz et al., 2004). Similar obser-
vations were made in Tunisia where the prevalence of PF was
higher in foci of zoonotic cutaneous leishmaniasis (Kallel Sellami
et al., 2007). The association between PF and leishmaniasis was
attributed to a cross-reaction between anti-Dsg1 auto-antibodies
and antibodies to sand ﬂy salivary proteins. Antibodies from PF
patients recognized salivary gland antigens from Lu. longipalpis
and P. papatasi (Qian et al., 2012; Zaraa et al., 2012) and anti-
Dsg1 antibodies were more prevalent in visceral leishmaniasis
patients in Tunisia (Kallel Sellami et al., 2007). Further investiga-
tion demonstrated that LJM11, a yellow protein from Lu. longipal-
pis, is the target of auto-antibodies in Brazilian PF patients (Qian
et al., 2012), while from P. papatasi ﬁve proteins of 12, 15, 30, 21
and 36 kDa proteins where recognized by pemphigus patients sera
(Zaraa et al., 2012). This suggests that antibodies made against
LJM11 may recognize Dsg1 triggering auto-antibody production.
There is no sequence similarity between Dsg1 and LJM11 and
apparently conformational mimotopes may be responsible for
the cross-reactivity in these two molecules (Qian et al., 2012). Fur-
ther studies are needed to identify these structural motifs in LJM11
that mimics the structure of dsg1.5. Practical applications ascribed to sand ﬂy salivary proteins
5.1. Salivary proteins as markers of exposure
The antigenic nature of certain salivary proteins provides an
opportunity for their use as indicators of host–vector contact.
The uniqueness of sand ﬂy salivary proteins, many being speciﬁc
only to sand ﬂies or to a particular species, makes them ideal as
markers of exposure to vectors species and important epidemio-
logical tools to measure of the risk of contracting leishmaniasis
and for vector surveillance and control programs (Andrade et al.,
2007; Barral et al., 2000; Vlkova et al., 2011). Importantly, the
use of sand ﬂy salivary proteins as markers of exposure offer sev-
eral advantages over the use of total saliva promising increased
speciﬁcity and the ability to produce large quantities of proteins
in a reproducible manner.
5.1.1. LJM11 and LJM17 as markers for exposure to Lu. longipalpis
The yellow proteins LJM11 and LJM17 from saliva of Lu.
longipalpiswere recognized by sera from humans living in endemic
areas of VL in Brazil (Souza et al., 2010; Teixeira et al., 2010). Sera
from dogs and foxes, important reservoirs of L. infantum, recog-
nized LJM17; LJM11 was only immunogenic in humans and dogs
(Teixeira et al., 2010). Importantly, LJM17 and LJM11 showed little
cross-reactivity with salivary proteins of Lu. intermedia, a sympat-
ric vector of CL in large parts of Brazil (Souza et al., 2010; Teixeira
et al., 2010). Encouragingly, in a large cohort of over 1000 subjects
from a VL endemic area in Brazil, the combined use of LJM11 and
LJM17 displayed a similar sensitivity as the use of total saliva val-
idating the promise of these antigens as speciﬁc markers of expo-
sure to Lu. longipalpis saliva (Souza et al., 2010). These two
molecules were also used successfully to monitor seroconversion
in chicken that can be used as sentinels to reﬂect the presence of
Lu. longipalpis in peri-domiciliary parts within VL endemic regions
(Table 4) (Soares et al., 2013).
5.1.2. PpSP32 as a marker for exposure to P. papatasi
PpSP32 was the immunodominant target of the antibody
response in humans naturally exposed to P. papatasi saliva inTunisia (Marzouki et al., 2012). Forty-two sera positive to whole
salivary gland extract and 24 negative controls were tested against
recombinant PpSP32. Sixty-four percent of saliva-exposed donors
showed a positive correlation between antibodies response against
saliva and rPpSP32 (Table 4). Despite the promising humoral
response to PpSP32, its speciﬁcity needs to be veriﬁed, at least with
regards to major sympatric vectors, to establish its usefulness as a
good marker of exposure to P. papatasi, the vector of L. major in this
country (Marzouki et al., 2012).
5.1.3. SP01B, SP01 and SP03B from P. perniciosus saliva as markers of
exposure
The apyrases rSP01B and rSP01 and the yellow protein rSP03B
from saliva of P. perniciosus, a principal vector of L. infantum in the
Mediterranean Basin, show promise as markers of canine exposure
to the vector and for estimating the risk of canine leishmaniasis in
the western Mediterranean area (Table 4) (Drahota et al., 2014).
Sera from three dogs repeatedly exposed to P. perniciosus bites spe-
ciﬁcally recognized the 3 molecules listed above. Additionally, a
strong positive correlationwas observed in the antibody titersmea-
sured against whole salivary extract and thesemolecule, suggesting
they can be good markers of exposure against P. perniciosus saliva
(Drahota et al., 2014). Morework is needed to establish the speciﬁc-
ity of these proteins against other vectors present in the same areas.
5.2. Salivary proteins as vaccines against leishmaniasis
To date several molecules from various vector species of sand
ﬂies, some with and others without any known activity, have dem-
onstrated immunogenicity and protective efﬁcacy against cutane-
ous and visceral leishmaniasis (Table 5). Following is an updated
account of the salivary vaccine candidates identiﬁed thus far.
5.2.1. PpSP15
PpSP15, (Table 2), was the ﬁrst salivary protein to be identiﬁed
as a potential vaccine (Oliveira et al., 2008; Valenzuela et al.,
2001a). Named after its molecular weight, PpSP15 was identiﬁed
by SDS–PAGE separation of salivary gland proteins from P. papatasi
(Valenzuela et al., 2001a). The proteins were grouped into three
fractions and only the one containing PpSP15 protected mice
against L. major infection. Immunization of mice with PpSP15 plas-
mid induced a delayed-type hypersensitivity response (DTH) that
was correlated to protection (Valenzuela et al., 2001a). The authors
also demonstrated that PpSP15-speciﬁc protection was cell-medi-
ated and antibody-independent. This seminal work established
that DTH-induction in immunized animals is the hallmark of pro-
tective salivary proteins. Seven years later, Oliveira et al. validated
the protective effect of PpSP15 against L. major in mice (Table 5)
(Oliveira et al., 2008). Furthermore, in addition to the induction
of a DTH, PpSP15-immunized mice expressed IFN-c and IL-12 2 h
after bites and showed an accelerated development of a Leish-
mania-speciﬁc immunity (Oliveira et al., 2008). Importantly, the
DTH-inducing salivary protein PpSP44 produced a Th2 response
in immunized mice that exacerbated L. major infections (Oliveira
et al., 2008). From thereon, only Th1-biased DTH-inducing salivary
proteins were considered as vaccine candidates for leishmaniasis.
5.2.2. Maxadilan
Morris et al. demonstrated that mice vaccinated with maxadi-
lan, the vasodilator in Lu. longipalpis saliva, developed both cellular
immunity and antibodies against this salivary protein that pro-
tected animals against L. major infection. The authors proposed
that maxadilan had an exacerbatory effect on L. major infection
that was neutralized by protective anti-maxadilan antibodies
(Table 5) (Morris et al., 2001). Maxadilan, a protein of 6.8 kDa, is
absent from Phlebotomus species and has only been described from
M. Abdeladhim et al. / Infection, Genetics and Evolution 28 (2014) 691–703 699some Lutzomyia vectors thus far (Table 2) (de Moura et al., 2013;
Valenzuela et al., 2004).
5.2.3. Identiﬁcation of vaccine candidates in the post-transcriptomic
era
Based on information from the salivary transcriptomes, plas-
mids encoding the most abundant secreted salivary proteins, irre-
spective of whether their identity and function were known, were
prioritized for screening. Classical vaccinology was used to identify
salivary vaccine candidates in rodents where vaccination of groups
of mice or hamsters with different vaccine candidates is feasible.
On the other hand, identiﬁcation of vaccines in larger and more rel-
evant animal models such dogs represented a challenge due to the
cost and logistics of such an endeavor. This led to the development
of reverse antigen screening (RAS) where large animals were
exposed to bites of a particular vector species, thus becoming
immune to the native salivary proteins secreted into the host.
Exposed animals were then injected with the salivary plasmids
at marked location in the animals (usually belly or thigh) along
with appropriate controls (Collin et al., 2009). The plasmids that
induced a DTH were further tested as recombinant proteins to
validate their immunogenicity. Furthermore, biopsies were taken
from the DTH site to determine the cytokine environment and
therefore, the molecules that induced a Th1-biased DTH.
5.2.4. Vaccine candidates identiﬁed by classical vaccinology (forward
immunology)
5.2.4.1. LJM19. LJM19, a 10.7 kDa protein from saliva of Lu. longipal-
pis (Table 3), induced a pronounced Th1 cellular immune response
in immunized hamsters characterized by an increase in IFN-c
expression in the absence of IL-10 or TGF-b (Gomes et al., 2008).
Hamsters immunized with LJM19 and challenged with L. chagasi
and L. braziliensis in the presence of Lu. longipalpis saliva were pro-
tected from visceral and cutaneous leishmaniasis, respectively
(Table 5) (Gomes et al., 2008; Tavares et al., 2011). Thus far,
LJM19 has only been identiﬁed from some Lutzomyia vector species
(de Moura et al., 2013; Kato et al., 2013; Valenzuela et al., 2004).
5.2.4.2. LJM11. LJM11, is a 43 kDa salivary protein from Lu. longipal-
pis that belongs to the yellow family of proteins (Table 2)
(Valenzuela et al., 2004). LJM11 was shown to be a DTH-inducing
protein that conferred protection against cutaneous leishmaniasis
in a mouse model of infection (Gomes et al., 2012a; Xu et al.,
2011). The protective effect was related to a DTH response medi-
ated by CD4+ T cells producing IFN-c, or both IFN-c and TNF-a,
at the bite site of LJM11-immunized mice 48 h after challenge with
infected sand ﬂies (Table 5) (Gomes et al., 2012a).
5.2.4.3. Linb-11. Linb-11, a small salivary protein of 4.5 kDa, was
identiﬁed from saliva of Lu. intermedia, another New World sand
ﬂy vector species (de Moura et al., 2013). Mice immunized with
Linb-11 were protected against a challenge with L. braziliensis par-
asite injected together with Lu. intermedia saliva (Table 5). Linb-11,
found only in Lu. intermedia sand ﬂies so far, was shown to induce a
transient cellular immune response in BALB/c mice that correlated
with an early predominance of IFN-c-secreting over IL-4- and
IL-10-secreting CD4 + T cells (Mbow et al., 1998).
5.2.5. Vaccine candidates identiﬁed by reverse antigen screening (RAS)
5.2.5.1. LJM17. LJM17 is a protein of 45 kDa from the saliva of Lu.
longipalpis (Table 2) that was shown to induce a strong DTH
response in dogs previously exposed to uninfected sand ﬂies bites.
Immunized dogs were primed with the plasmid coding for this
protein and boosted with a LJM17 recombinant protein (rLJM17)
(Collin et al., 2009). PBMC from immunized dogs produced a high
amount of IFN- upon in vitro stimulation with rLJM17, conﬁrmingthe Th1 proﬁle of the generated immune response. Additionally,
immunized dogs showed a strong predominantly IgG2 humoral
immune response to LJM17 (Table 5). Biopsies taken from the
DTH-site of bite 48 h after exposing these dogs to uninfected sand
ﬂies showed a cellular inﬁltrate dominated by CD3 T cells and mac-
rophages. These inﬁltrated cells expressed high levels of IFN- and
IL-12 corroborating the result obtained from PBMC stimulation
(Collin et al., 2009). Importantly, in an in vitro killing assay,
autologous T cells from immunized dogs signiﬁcantly reduced
the percent of infected macrophages as well as the number of
amastigotes per cell (Collin et al., 2009).
5.2.5.2. Lufaxin (LJL143). The immune response seen in dogs immu-
nized with LJM17 was also observed in dogs immunized with
LJL143 (Lufaxin) (Collin et al., 2009). PBMC from LJL143-immu-
nized dogs produced a high amount of IFN-c upon in vitro stimula-
tion with recombinant LJL143 and showed a strong IgG2-biased
humoral response (Table 5). Interestingly, the immune response
at the site of bite differed depending on the number of ﬂies used
in the challenge. Following exposure to bites of 20 sand ﬂies,
TGF-b was the dominant cytokine induced with a low expression
of IFN-c, IL-12 and IL-4. In contrast, a high level of IFN-c and a
low level of IL-4 were induced when these dogs were exposed to
bites from 5 sand ﬂies (Collin et al., 2009).
5.2.6. Vaccines combining Leishmania antigens and sand ﬂy salivary
proteins
Up to date, there is no vaccine against human leishmaniasis
despite the large portfolio of promising Leishmania antigens.
Recent data from vaccination with sand ﬂy salivary antigens sug-
gest that immunity to sand ﬂy saliva may promote a speciﬁc and
protective immunity to Leishmania (Gomes et al., 2012a; Oliveira
et al., 2008). These ﬁndings may suggest that a combination of a
sand ﬂy salivary protein with a Leishmania antigen may produce
a more robust and protective immune response. Some groups have
tested combinations of sand ﬂy saliva or salivary proteins with
Leishmania parasites with promising results. In the study by Agu-
iar-Soares et al., a vaccine composed of L. braziliensis antigens adju-
vanted with saponin and Lu. longipalpis salivary gland extract
(LBSapSal vaccine) was tested in dogs. This combination vaccine
elicited both anti-Leishmania and anti-saliva humoral and cellular
immune responses and resulted in a reduction of the splenic para-
site load in immunized dogs as compared to control groups
(Aguiar-Soares et al., 2014). Recently, a vaccine combination of a
single sand ﬂy salivary protein (PpSP15) with live non-pathogenic
L. tarentolae expressing the cysteine proteases A and B resulted in a
better immunity and better protection against cutaneous leishma-
naniasis than animals vaccinated with PpSP15 alone or with non-
pathogenic L. tarentolae expressing the cysteine proteases A and
B without the salivary protein (Zahedifard et al., 2014). It is impor-
tant to note that this increase in protection was only observed
when animals were ﬁrst primed with PpSP15 DNA and then
boosted with PpSP15 DNA and live CPA/CPB/EGFP-expressing
recombinant L. tarontolae (Zahedifard et al., 2014). Apparently
the priming with the salivary is important since on a separate
study animals vaccinated simultaneously with KMP11 and the sal-
ivary protein LJM19 showed no improvement in protective efﬁcacy
over the KMP11 or LJM19 vaccines alone (da Silva et al., 2011).
These studies suggest that priming with a sand ﬂy salivary protein
may be required for a vaccine that envision a combination of a sand
ﬂy salivary protein and a Leishmania antigen.
5.3. Vector-transmitted models of infection
Several studies highlighted the signiﬁcance of vector-transmit-
ted models of infection in the assessment of Leishmania vaccines. In
Table 4
Sand ﬂy salivary proteins characterized as markers of vector exposure.
Sand ﬂy species Marker of exposure Species tested Type of Leishmaniasis References
Lu. longipalpis LJM11 Humans, dogs, chicken VL Teixeira et al. (2010))
Lu. longipalpis LJM17 Humans, dogs, foxes, chicken VL Teixeira et al. (2010)
P. papatasi PpSP32 Humans CL Marzouki et al. (2012)
P. perniciosus SP01B Dogs VL Drahota et al. (2014)
P. perniciosus SP01 Dogs VL Drahota et al. (2014)
P. perniciosus SP03B Dogs VL Drahota et al. (2014)
VL: Visceral Leishmaniasis; CL: Cutaneous Leishmaniasis.
Table 5
Salivary vaccine candidates from different sand ﬂies species.
Sand ﬂy
species
Vaccine
candidate
Protect against Nature of protective
immune response
Model Family of the
protein
or protein
Function
P. papatasi PpSP15 L. major (Valenzuela et al., 2001a;
Oliveira et al., 2008)
Th1, DTH Mice OBP/SL1 Inhibitor of contact
activation
Lu. longipalpis Maxadilan L. major (Morris et al., 2001) Th1, Humoral immune
response
Mice Maxadilan Vasodilatator
Lu. longipalpis LJM19 L. infantum chagasi, L. braziliensis
(Gomes et al., 2008; Tavares et al.,
2011)
Th1 Hamsters
Lu. longipalpis LJM11 L. major (Xu et al., 2011; Gomes
et al., 2012a)
Th1, DTH Mice Yellow Serotonin binding
Lu. intermedia Linb-11 L. brazileinsis (de Moura et al., 2013) Th1 Mice
Lu. longipalpis LJM17 L. infantum chagasi (Collin et al.,
2009)
Th1, DTH, IgG2 Dogs Yellow Serotonin binding
Lu. longipalpis LJL143 L. infantum chagasi (Collin et al.,
2009)
Th1, DTH, IgG2 Dogs Lufaxin Anti-coagulant
L., Leishmania; Th1, T helper type 1 immune response; DTH, delayed-type hypersensitivity; IgG2, Immunoglobulin G class 2.
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major caused a persistent inﬁltration of neutrophils to the site
of bite that promoted parasite establishment (Peters et al.,
2008). Vector-transmission by Lu. longipalpis also enhanced L.
mexicana infection, attributed to regurgitation of the promastigote
secretory gel alongside parasites (Rogers et al., 2004). Moreover,
the modulatory properties of saliva have been associated with
exacerbation of L. major infection (Gomes and Oliveira, 2012).
Recently, vector-transmission of L. infantum and L. donovani by
bites of Lu. longipalpis succeeded causing fatal visceralizing infec-
tions in hamsters and reﬂected disease characteristics similar to
those observed in nature (Aslan et al., 2013). Taken together, it
is not surprising that the enhanced virulence of vector-transmis-
sion abrogated the protection observed following needle challenge
of vaccinated animals (Peters et al., 2009) or led to a different out-
come to that observed following needle challenge (Rogers et al.,
2006). Today, vector-transmission is considered the golden stan-
dard for testing Leishmania vaccines (Gomes et al., 2012a,b;
Peters et al., 2012) and the closest experimental model to mimic
what occurs naturally.
For salivary vaccines, vector-transmitted models are doubly
consequential. Apart from testing the vaccine against a stringent
challenge, they permit the evaluation of the adaptive immune
response to the native salivary vaccine candidate injected at the site
of bite. Moreover, the proteinwill be injected in physiological quan-
tities and assessed in the context of the other salivary proteins pres-
ent in saliva and other vector-derived factors co-injected during
infected vector-bites. Promisingly, vector-challenge of animals pre-
viously exposed to saliva or immunizedwith salivary vaccines dem-
onstrated the powerful and long-term protection of mice against
leishmaniasis (Gomes et al., 2012a; Kamhawi et al., 2000; Teixeira
et al., 2014).5.4. From rodent models to humans
The selection of vaccine candidates against leishmaniasis,
including salivary proteins, has been traditionally undertaken in
rodent models of infection. A leishmaniasis vaccine needs to
induce a robust T cell immunity that depends on recognition of
speciﬁc epitopes by major histocompatibility complex molecules.
With that in mind, the immunogenicity and protective effects of
an antigen in rodents may not necessarily be observed in humans.
The variability of the immune response in different hosts was
exempliﬁed in by studies of the salivary vaccine candidate
LJM19. Immunization of hamsters with LJM19 protected against
fatal progressive VL but was non-immunogenic in dogs (Collin
et al., 2009; Gomes et al., 2008). The danger of choosing the wrong
antigen as a vaccine can be overcome by testing their immunoge-
nicity in target hosts; for leishmaniasis vaccines, these are either
dogs or humans.
To date only one study reported the immunogenicity of salivary
proteins in dogs. For the rest, the focus remained on the effect of
total saliva on target species. In dogs, immunization with both
LJL143 and LJM17 induced an in vivo Th1-biased DTH, IFN-c-
production by PBMC and in vitro killing of Leishmania parasites
by T cells obtained from immunized animals (Collin et al., 2009).
Recently, dogs immunized with a combination vaccine composed
of L. braziliensis antigen adjuvanted with saponin and Lu. longipalpis
saliva developed Leishmania-speciﬁc T cells and exhibited a
reduced splenic parasite load compared to controls (Aguiar-
Soares et al., 2014).
In human studies, volunteers experimentally or naturally
exposed to sand ﬂy bites developed a distinct immune response
to saliva (Abdeladhim et al., 2011; Oliveira et al., 2013; Vinhas
et al., 2007). In one study in Tunisia, PBMC obtained from
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of P. papatasi induced activation of IL-10-producing CD8+ T cells
and IFN-c-producing CD4+ T cells when the effect of IL-10 was
blocked (Abdeladhim et al., 2011).In another study, cellular
immune response to sand ﬂy salivary proteins was persistent for
one year. In this study, PBMC from human volunteers experimen-
tally exposed to Lu. longipalpis bites displayed increased frequency
of CD4+ and CD8+ T lymphocytes expressing CD25+ with an
increase in the secretion of IFN-c and IL-10 upon stimulation with
sand ﬂy saliva (Vinhas et al., 2007). In another study, subjects from
Mali and naturally exposed to P. duboscqi bites were challenged by
bites of three uninfected sand ﬂies and these individuals produced
a Th1-biased DTH response at the bite site (Oliveira et al., 2013).
This immune response observed in these individuals is the same
response observed in rodents and is the hallmark of a protective
immune response against leishmaniasis induced by sand ﬂy sali-
vary proteins (Gomes et al., 2012a). It is important to note that
the DTH response to sand ﬂy saliva observed in these individuals
was maintained to mid-life in 48% of tested subjects (Oliveira
et al., 2013), relevant to the consideration of salivary proteins as
leishmaniasis vaccines. Interestingly, PBMC from a larger cohort
in the same study area exhibited a varied immune response to sal-
iva where around 25% of individuals produced a Th1 response to
sand lfy salivary proteins, 25% to a Th2 immune response and
the rest of the individuals showed a mixed Th1/Th2 proﬁle. This
suggest that not all individuals respond in the same way to sand
ﬂy salivary proteins and these differences may account for the dif-
ferent outcomes of leishmaniasis in a population that is constantly
bitten by sand ﬂies.
Despite of the limited number of reports, it is evident that sand
ﬂy saliva is immunogenic in humans. Further studies are needed to
identify distinct salivary proteins from saliva of vectors that are
immunogenic in targeted species for consideration as components
of Leishmania vaccines.
5.5. Perspectives on salivary proteins as vaccines
There are no human vaccines against any form of leishmaniasis
to date. The immunogenicity of certain salivary proteins and their
capacity to confer powerful protection in various animal models
argues strongly for their inclusion in Leishmania vaccines. How-
ever, a potential challenge to salivary proteins as vaccines is that
some may have functions that affect human physiology such
LJL143, an anti-coagulant, or maxadilan, a potent vasodilator. In
large animals this did not represent a problem since dogs immu-
nized with LJL143 or with LJM17 were shown to be safe and with
no adverse reactions even after a robust immunization protocol
(Collin et al., 2009).
The speciﬁcity of salivary proteins also poses an obvious restric-
tion to their use as vaccines particularly since different vector spe-
cies transmit the same Leishmania species in several parts of the
world. As such, a salivary vaccine candidate should ideally be con-
served across vector species or alternately target major vectors
such P. argentipes, the only vector of L. donovani in Nepal, India, Ben-
gladesh and Sri Lanka (Lane et al., 1990; Picado et al., 2010); P. ori-
entalis the main vector of L. donovani in Sudan, Ethiopia and Kenya
(Elnaiem, 2011); and Lu. longipalpis, the main vector of L. infantum
chagasi in Latin America. Together, these regions contain over 90%
of global VL cases (http://www.who.int/gho/neglected_ diseases/
leishmaniasis/en/). Though salivary proteins may be speciﬁc to a
sand ﬂy species, several studies have demonstrated that for the
most part these molecules are conserved across the distribution
range of a species. P. duboscqi transcriptomes of ﬂies originating
from Kenya and Mali in East Africa and West Africa, respectively,
showed a high degree of conservancy (Kato et al., 2006) while anal-
ysis of PpSP15 from P. papatasi ﬁeld-caught sand ﬂies from Sudanand from colonies originating from Egypt, Jordan, Israel and Saudi
Arabia showed no signiﬁcant polymorphisms (Elnaiem et al.,
2005). Another recent study of the apyrases of P. ariasi collected
from different regions in southwest Europe and northeast Africa
also found no variation (Mahamdallie and Ready, 2012).
Of note, several of our studies have demonstrated that immu-
nity to salivary proteins initiate a rapid immune response follow-
ing an infective bite that seems to set the scene for the
development of a robust Leishmania-speciﬁc immunity with mini-
mal pathology (Gomes et al., 2012a; Oliveira et al., 2008). If driving
a protective immunity against the parasites is achievable in the
context of a vaccine it will diminish the biggest limitation faced
by these molecules as vaccines.
6. Conclusion
The study of arthropod saliva exploded in the last decade facil-
itated by the arrival of the era of transcriptomics and proteomics.
For sand ﬂies, the discovery of new salivary proteins, elucidating
new activities and functions and establishing the immunogenicity
of some in various mammals reﬂects the diverse ways by which
these molecules inﬂuence our condition. The advent of more pow-
erful techniques such us deep sequencing and other functional
genomic approaches may yet reveal that we are only seeing the
tip of the iceberg, or for vector biologists, just the tip of the
proboscis.
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